The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials

Ahmed M Younes; Basem M Mishriky; James R Powell; Doyle M Cummings

doi:10.1016/j.diabres.2021.108878

The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials

Diabetes Res Clin Pract. 2021 Jul:177:108878. doi: 10.1016/j.diabres.2021.108878. Epub 2021 May 29.

Authors

Ahmed M Younes¹, Basem M Mishriky², James R Powell³, Doyle M Cummings⁴

Affiliations

¹ Department of Internal Medicine, East Carolina University, United States. Electronic address: younesa19@ecu.edu.
² Department of Internal Medicine, East Carolina University, United States. Electronic address: mishrikyb@ecu.edu.
³ Department of Internal Medicine, East Carolina University, United States. Electronic address: powellj@ecu.edu.
⁴ Department of Family Medicine, East Carolina University, United States. Electronic address: cummingsd@ecu.edu.

PMID: 34058302
DOI: 10.1016/j.diabres.2021.108878

Abstract

There may be hesitancy in prescribing GLP-1RA in older adults. On pooling results from the CVOTs comparing GLP-1RA to placebo, there was a significantly lower incidence of MACE favoring GLP-1RA in both younger and older adults. GLP-1RA should be considered in high risk patients regardless of age.

Keywords: Cardiovascular outcome trials; GLP-1RA; Older adults; Type 2 diabetes.

MeSH terms

Age Factors
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2 / drug therapy
Diabetes Mellitus, Type 2 / epidemiology
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / therapeutic use

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents